Immunome (IMNM) Capital Expenditures Growth (1y) (2020 - 2026)

Immunome (IMNM) Capital Expenditures Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 38.18%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -27.93%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 227.76%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.57%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Immunome 2.49 Bn 1.91 Bn - -18.09%

Historic Data

Download Data
DateValue
Mar 31, 2026 -18.09%
Dec 31, 2025 255.15%
Sep 30, 2025 185.83%
Jun 30, 2025 -160.76%
Mar 31, 2025 517.00%
Dec 31, 2024 1,875.44%
Sep 30, 2024 1,274.81%
Jun 30, 2024 1,655.16%
Mar 31, 2024 166.37%
Dec 31, 2023 -20.83%
Jun 30, 2023 31.18%
Mar 31, 2023 3,616.67%
Dec 31, 2022 -6.49%
Jun 30, 2022 808.33%
Mar 31, 2022 -80.65%
Dec 31, 2021 67.39%
Sep 30, 2021 -104.03%
Jun 30, 2021 -106.65%
Mar 31, 2021 -43.64%
Dec 31, 2020 -31.34%